COVID-19 vaccines are being hurried through the approval process in Russia and China despite lack of testing and potential dangers, scientists have warned.
Corner-cutting has come to define the vaccine research and development process in both countries as the search for a way to stop the pandemic has become entangled with geopolitics and great power rivalry.
Two leading vaccine candidates being rolled out for emergency use, one developed by Moscow's Gamaleya Institute and the other by Tianjin-based CanSino Biologics, have been criticized.
The CanSino vaccine uses a particularly large amount of Ad5 and could induce fevers.
There is also concern among scientists that Ad5-based vaccines may increase patient vulnerability to HIV, though this has yet to be confirmed outside of HIV-specific vaccine trials.
China has already begun negotiations for use of its vaccine in partner countries before even efficacy at home has been established.
Whoever arrives at a working vaccine first stands to control the momentum of the U.S.-China-Russia great power competition.
https://spectator.org/russia-china-rush-through-potentially-faulty-vaccines/
No comments:
Post a Comment